COCHW · Envoy Medical, Inc.

Summary

Envoy Medical, Inc. closed a $30.0 million public offering of 47,946,150 shares of Class A Common Stock (or pre-funded warrants), 45,000,000 Series A-1 Warrants, and 75,000,000 Series A-2 Warrants at $0.40 per share and accompanying warrants on February 12, 2026. The offering provides gross proceeds of $30.0 million upfront and up to $48.0 million more if warrants are exercised, funding FDA pivotal clinical study for Acclaim CI device.

Key takeaways

• Commenced best efforts public offering on February 11, 2026, closing February 12, 2026
• Issued 47,946,150 shares Class A Common Stock and 27,053,850 pre-funded warrants
• Issued 45,000,000 Series A-1 Warrants and 75,000,000 Series A-2 Warrants to purchase Common Stock
• Gross proceeds $30.0 million; potential additional $48.0 million from warrant exercises
• Certain directors/officers purchased 2,250,000 shares for $0.9 million; 35.6% shareholder bought 18,750,000 shares for $7.5 million
• H.C. Wainwright & Co., LLC acted as exclusive placement agent; issued Placement Agent Warrants for 3,750,000 shares